6.2.1.2.1. active surveillance - inclusion criteria. guidance regarding selection criteria limited lack data prospective rcts. consequence, panel undertook international collaborative study involving healthcare practitioners patients develop consensus statements deferred treatment curative intent localised pca, covering domains (detective study) , well formal sr various protocols . criteria often published include: isup grade group 1, clinical stage ct1c ct2a, psa < 10 ng/ml psa-d < 0.15 ng/ml/cc, based systematic biopsy schemes . latter threshold remains controversial . criteria supported detective study consensus. agreement maximum number systematic cores involved cancer maximum percentage core involvement (ci), although recognition extensive disease mri exclude men as, even though firm definition this, especially targeted biopsies confirm isup grade group 1 . movember consensus group, consisting 27 healthcare professional 12 lived experience participants across world, agreed isup grade group mri important criteria determining eligibility . sr meta-analysis found three clinico-pathological variables significantly associated reclassification, high psa-d, > 2 positive cores (on systematic biopsies) african-american descent . review risk progression african-american men also indicated potential increased risk progression, association strong enough discourage african-american men undergoing as, thorough confirmatory testing important . addition, previous pathology consensus group suggested excluding men following features present: predominant ductal carcinoma (including pure idc), cribriform histology, sarcomatoid carcinoma, small cell carcinoma, epe lvi needle biopsy perineural invasion . multi-disciplinary consensus conference germline testing suggested genetic implementation framework management pca . based consensus, brca2-gene testing recommended discussions could performed men family history prostate, breast ovarian cancers. however, nature discussions positive result influences management beyond scope project. currently, brca2 mutation exclude patient tumour factors otherwise favourable. furthermore, included programmes, patients known brca2 mutation cautiously monitored time robust data available.